Prostvac: Difference between revisions
CSV import |
CSV import |
||
| (One intermediate revision by the same user not shown) | |||
| Line 32: | Line 32: | ||
{{stub}} | {{stub}} | ||
{{No image}} | |||
__NOINDEX__ | |||
Latest revision as of 00:10, 18 March 2025
Prostvac is an investigational immunotherapy for the treatment of prostate cancer. It is being developed by Bavarian Nordic, a biotechnology company specializing in vaccines.
Overview[edit]
Prostvac uses a virus as a vector to deliver antigens to the immune system. The antigens are designed to stimulate an immune response against prostate-specific antigen (PSA), a protein that is overexpressed in prostate cancer cells.
Clinical Trials[edit]
Prostvac has been tested in several clinical trials. In a Phase II trial, Prostvac was shown to extend the median survival of patients with metastatic castration-resistant prostate cancer by 8.5 months compared to a placebo. However, a subsequent Phase III trial did not meet its primary endpoint of improving overall survival.
Mechanism of Action[edit]
Prostvac works by stimulating the body's immune system to attack prostate cancer cells. It does this by using a virus to deliver antigens to the immune system. These antigens are designed to stimulate an immune response against prostate-specific antigen (PSA), a protein that is overexpressed in prostate cancer cells.
Side Effects[edit]
The most common side effects of Prostvac are flu-like symptoms, including fever, chills, and fatigue. These symptoms are typically mild and temporary.
